<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559803</url>
  </required_header>
  <id_info>
    <org_study_id>GHR-002</org_study_id>
    <nct_id>NCT03559803</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer</brief_title>
  <official_title>A Prospective Study of Dynamic Monitoring Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perspectives:

      To analyse if the change of specific immune response will correlate with clinical effect of
      advanced cervix cancer after radio-chemotherapy.

      To evaluate the specific immune response throughout monitor the change of the programmed
      death-1(PD-1) in CD8 T cell and CD4 T cell and Treg cell in blood at baseline, before first
      brachytherapy and before the last brachytherapy in the advanced Cervix Cancer patients.

      To use immunohistochemistry (IHC) technique to monitor the change of programmed death-ligand
      1 (PD-L1),CD68,CD8,CD4,PD1 and Treg expression in biopsy at baseline, before first
      brachytherapy and before the last brachytherapy in the advanced Cervix Cancer patients.

      To detect the change of T cell receptor(TCR) repertoire and Tumor mutation burden (TMB) at
      baseline, before first brachytherapy and before the last brachytherapy in the advanced Cervix
      Cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical cancer is the fourth most common cancer among women worldwide. At present, patients
      with cervical cancer are treated with radical hysterectomy and pelvic lymphadenectomy or
      chemoradiation. To improve the prognosis of cervical cancer patients, novel immunotherapeutic
      strategies need to be developed. Now there are some clinical phase I/II trials ongoing to
      assess the effects of ipilimumab, pembrolizumab and nivolumab in advanced cervical cancer,but
      information on the clinical significance of PD-L1 expression in cervical cancer is largely
      lacking.In this study, the investigator's primary objective:

      To analyse if the change of specific immune response will correlate with clinical effect of
      advanced cervix cancer after radio-chemotherapy.

      To evaluate the specific immune response throughout monitor the change of PD-1 in CD8 T cell
      and CD4 T cell and Treg cell in blood at baseline, before first brachytherapy and before the
      last brachytherapy in the advanced Cervix Cancer patients.

      To use IHC technique to monitor the change of PD-L1, CD68,CD8,CD4,PD1 and Treg expression in
      biopsy at baseline, before first brachytherapy and before the last brachytherapy in the
      advanced Cervix Cancer patients.

      To detect the change of TCR repertoire and TMB at baseline, before first brachytherapy and
      before the last brachytherapy in the advanced Cervix Cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of expression of PD-L1+ on cervix biopsies</measure>
    <time_frame>From baseline,3 weeks,2 months</time_frame>
    <description>The biopsy was collected at baseline,3 weeks,2 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of expression of PD1 on the non-regulatory CD4+ and CD8+ lymphocytes and Treg cells</measure>
    <time_frame>baseline,3 weeks,2 months</time_frame>
    <description>The blood was collected at baseline,3 weeks,2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The diversity of T-cell Repertoire in cervix biopsies and blood, respectively</measure>
    <time_frame>baseline,3 weeks,2 months</time_frame>
    <description>The blood and biopsies were collected at baseline,3 weeks,2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of expression of CD8+PD1+ lymphocytes infiltrate on cervix biopsies</measure>
    <time_frame>baseline,3 weeks,2 months</time_frame>
    <description>The biopsy was collected at baseline,3 weeks,2 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).</description>
    <arm_group_label>Cisplatin</arm_group_label>
    <other_name>radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18-70 years.

          2. All FIGO stages cervical cancers which are the matter for radiochemotherapy and
             exclusive brachytherapy indications.

          3. ECOG:0-1.

          4. Ability to give informed consent.

        4. Patients must be affiliated to a Social Security System. 6. Patient information and
        written informed consent form signed.

        Exclusion Criteria:

          1. Known autoimmune disorder.

          2. History of HIV and/ or active hepatitis infection.

          3. History of pelvic radiation or radio-chemotherapy.

          4. Recurrent or metastatic cervical cancer.

          5. Contra-indication for cisplatin.

          6. Patient pregnant and/or breastfeeding.

          7. Patients with psychological or familial disease potentially hampering compliance with
             the study protocol and follow-up schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guizhou Province People's Hospital</name>
      <address>
        <city>Guizhou</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jayshree RS, Sreenivas A, Tessy M, Krishna S. Cell intrinsic &amp; extrinsic factors in cervical carcinogenesis. Indian J Med Res. 2009 Sep;130(3):286-95. Review.</citation>
    <PMID>19901438</PMID>
  </reference>
  <reference>
    <citation>Folkl A, Bienzle D. Structure and function of programmed death (PD) molecules. Vet Immunol Immunopathol. 2010 Mar 15;134(1-2):33-8. doi: 10.1016/j.vetimm.2009.10.006. Epub 2009 Oct 14. Review.</citation>
    <PMID>19931186</PMID>
  </reference>
  <reference>
    <citation>Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, Xu Y, Fan J. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009 Feb 1;15(3):971-9. doi: 10.1158/1078-0432.CCR-08-1608.</citation>
    <PMID>19188168</PMID>
  </reference>
  <reference>
    <citation>Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer. 2014 May;50(7):1361-9. doi: 10.1016/j.ejca.2014.01.018. Epub 2014 Feb 15.</citation>
    <PMID>24548766</PMID>
  </reference>
  <reference>
    <citation>Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, Scolyer RA. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015 May;28(3):245-53. doi: 10.1111/pcmr.12340. Epub 2014 Dec 22.</citation>
    <PMID>25477049</PMID>
  </reference>
  <reference>
    <citation>Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):15-24. doi: 10.1007/s10549-014-2988-5. Epub 2014 May 20.</citation>
    <PMID>24842267</PMID>
  </reference>
  <reference>
    <citation>Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011 Feb 15;128(4):887-96. doi: 10.1002/ijc.25397.</citation>
    <PMID>20473887</PMID>
  </reference>
  <reference>
    <citation>Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, van der Velden J, Kenter GG, de Gruijl TD, Jordanova ES. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016 Jul;29(7):753-63. doi: 10.1038/modpathol.2016.64. Epub 2016 Apr 8.</citation>
    <PMID>27056074</PMID>
  </reference>
  <reference>
    <citation>Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh D, Ahn YC, Jung SH, Ahn MJ, Park K, Zo JI, Shim YM, Sun JM. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26.</citation>
    <PMID>26623522</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W, Ma Y, Zhao H, Huang Y, Xue C, Huang P, Hu Z, Zhao Y, Zhang L. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015 Mar;32(3):86. doi: 10.1007/s12032-015-0501-6. Epub 2015 Feb 22.</citation>
    <PMID>25702326</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>You Lu</investigator_full_name>
    <investigator_title>Chair of Department of Thoracic Oncology</investigator_title>
  </responsible_party>
  <keyword>Cervical Cancer</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Concurrent Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

